Issue 8, 2017

Recent advances in nanomedicines for the treatment of rheumatoid arthritis

Abstract

Rheumatoid arthritis (RA) is a severe systemic inflammatory disease. It is often associated with serious cartilage destruction and massive inflammatory infiltration, which might ultimately cause disability, wide complications and reduced life quality. Current clinical treatments of RA show several drawbacks such as high doses, frequent administration and serious side effects. These limitations have motivated tremendous expansion of the research and application of nanomedicines in RA therapy. In this review, we summarize the cutting edge progress in nanomedicines for the treatment of RA and discuss the application of various targeting strategies. Additionally, we also discuss the pivotal challenges to be addressed, as well as future perspectives.

Graphical abstract: Recent advances in nanomedicines for the treatment of rheumatoid arthritis

Article information

Article type
Review Article
Submitted
27 Mar 2017
Accepted
31 May 2017
First published
31 May 2017

Biomater. Sci., 2017,5, 1407-1420

Recent advances in nanomedicines for the treatment of rheumatoid arthritis

Q. Wang and X. Sun, Biomater. Sci., 2017, 5, 1407 DOI: 10.1039/C7BM00254H

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements